{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T22:02:48Z","timestamp":1793916168605,"version":"4.8.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T00:00:00Z","timestamp":1735948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T00:00:00Z","timestamp":1735948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100005329","name":"Natural Science Foundation of Guizhou Province","doi-asserted-by":"publisher","award":["QianKeHe Basics - ZK[2023] Key 042"],"award-info":[{"award-number":["QianKeHe Basics - ZK[2023] Key 042"]}],"id":[{"id":"10.13039\/501100005329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005329","name":"Natural Science Foundation of Guizhou Province","doi-asserted-by":"publisher","award":["Qiankehe Cooperation Platform Talents [2021] Postdoctoral Station 007"],"award-info":[{"award-number":["Qiankehe Cooperation Platform Talents [2021] Postdoctoral Station 007"]}],"id":[{"id":"10.13039\/501100005329","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Research Project of Education Department of Guizhou Province","award":["QianJiaoJi [2023]037"],"award-info":[{"award-number":["QianJiaoJi [2023]037"]}]},{"name":"Subject Excellent Reserve Talent Project","award":["gyfyxkrc-2023-14"],"award-info":[{"award-number":["gyfyxkrc-2023-14"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-024-06035-4","type":"journal-article","created":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T03:36:24Z","timestamp":1735961784000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Risk analysis of cardiovascular toxicity in patients with lymphoma treated with CD19 CAR T cells"],"prefix":"10.1186","volume":"23","author":[{"given":"Yang","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoshuang","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanbin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixu","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4297-1839","authenticated-orcid":false,"given":"Feiqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanju","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,4]]},"reference":[{"issue":"10438","key":"6035_CR1","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1016\/S0140-6736(23)02705-8","volume":"403","author":"E Silkenstedt","year":"2024","unstructured":"Silkenstedt E, Salles G, Campo E, et al. B-cell non-Hodgkin lymphomas. Lancet. 2024;403(10438):1791\u2013807.","journal-title":"Lancet"},{"issue":"27","key":"6035_CR2","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","volume":"32","author":"SF Barrington","year":"2014","unstructured":"Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the international conference on malignant lymphomas imaging working group. J Clin Oncol. 2014;32(27):3048\u201358.","journal-title":"J Clin Oncol"},{"issue":"1","key":"6035_CR3","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ijrobp.2015.01.008","volume":"92","author":"L Specht","year":"2015","unstructured":"Specht L, Dabaja B, Illidge T, et al. Modern radiation therapy for primary cutaneous lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2015;92(1):32\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"6035_CR4","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1182\/blood.2022015851","volume":"140","author":"E Campo","year":"2022","unstructured":"Campo E, Jaffe ES, Cook JR, et al. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the clinical advisory committee. Blood. 2022;140:1229\u201353.","journal-title":"Blood"},{"issue":"4","key":"6035_CR5","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235\u201342.","journal-title":"N Engl J Med"},{"issue":"19","key":"6035_CR6","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","volume":"363","author":"A Younes","year":"2010","unstructured":"Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363(19):1812\u201321.","journal-title":"N Engl J Med"},{"issue":"4","key":"6035_CR7","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1182\/blood-2016-07-729954","volume":"129","author":"K Krysiak","year":"2017","unstructured":"Krysiak K, Gomez F, White BS, et al. Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma. Blood. 2017;129(4):473\u201383.","journal-title":"Blood"},{"issue":"9","key":"6035_CR8","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1038\/s41591-022-01959-0","volume":"28","author":"NJ Haradhvala","year":"2022","unstructured":"Haradhvala NJ, Leick MB, Maurer K, et al. Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma. Nat Med. 2022;28(9):1848\u201359.","journal-title":"Nat Med"},{"issue":"3","key":"6035_CR9","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/S1074-7613(04)00051-2","volume":"20","author":"X Zhang","year":"2004","unstructured":"Zhang X, Schwartz JC, Guo X, et al. Structural and functional analysis of the costimulatory receptor programmed death-1. Immunity. 2004;20(3):337\u201347.","journal-title":"Immunity"},{"issue":"5","key":"6035_CR10","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1007\/s00432-024-05765-8","volume":"150","author":"F Eigendorff","year":"2024","unstructured":"Eigendorff F, Filimonova I, Scholl S, et al. Effective bridging strategies prior to infusion with tisagenlecleucel results in high response rates and long-term remission in relapsed\/refractory large B-cell lymphoma: findings from a German monocentric study. J Cancer Res Clin Oncol. 2024;150(5):224.","journal-title":"J Cancer Res Clin Oncol"},{"key":"6035_CR11","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with b-cell lymphoblastic leukemia. N Engl J Med. 2018;378:439\u201348.","journal-title":"N Engl J Med"},{"key":"6035_CR12","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large b-cell lymphoma. N Engl J Med. 2019;380:45\u201356.","journal-title":"N Engl J Med"},{"key":"6035_CR13","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","volume":"22","author":"SJ Schuster","year":"2021","unstructured":"Schuster SJ, Tam CS, Borchmann P, et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021;22:1403\u201315.","journal-title":"Lancet Oncol"},{"issue":"10","key":"6035_CR14","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1038\/s41591-022-01969-y","volume":"28","author":"E Bachy","year":"2022","unstructured":"Bachy E, Le Gouill S, Di Blasi R, et al. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nat Med. 2022;28(10):2145\u201354.","journal-title":"Nat Med"},{"key":"6035_CR15","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396:839\u201352.","journal-title":"Lancet"},{"key":"6035_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103807","volume":"179","author":"S Chen","year":"2022","unstructured":"Chen S, Zhang Y, Fang C, et al. Donor-derived and off-the-shelf allogeneic anti-CD19 CAR T-cell therapy for R\/R ALL and NHL: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2022;179: 103807.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"6035_CR17","doi-asserted-by":"publisher","first-page":"77.e1","DOI":"10.1016\/j.jtct.2023.10.017","volume":"30","author":"CA Jacobson","year":"2024","unstructured":"Jacobson CA, Munoz J, Sun F, et al. Real-world outcomes with chimeric antigen receptor T cell therapies in large b cell lymphoma: a systematic review and meta-analysis. Transplant Cell Ther. 2024;30(1):77.e1-77.e15.","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"6035_CR18","doi-asserted-by":"publisher","first-page":"e142","DOI":"10.1016\/j.clml.2023.12.012","volume":"24","author":"G Elgohary","year":"2024","unstructured":"Elgohary G, Yang Y, Gergis M, et al. Chimeric antigen receptor T-cell therapy for large b-cell lymphoma patients with central nervous system involvement, a systematic review and meta-analysis. Clin Lymphoma Myeloma Leuk. 2024;24(4):e142\u201351.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"15","key":"6035_CR19","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.3390\/cancers13153912","volume":"13","author":"W Lei","year":"2021","unstructured":"Lei W, Xie M, Jiang Q, Xu N, Li P, Liang A, et al. Treatment-related adverse events of chimeric antigen receptor T-cell (CAR T) in clinical trials: a systematic review and meta-analysis. Cancers (Basel). 2021;13(15):3912.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"6035_CR20","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.jcyt.2020.01.015","volume":"22","author":"JX Cao","year":"2020","unstructured":"Cao JX, Wang H, Gao WJ, You J, Wu LH, Wang ZX, et al. The incidence of cytokine release syndrome and neurotoxicity of CD19 chimeric antigen receptor-T cell therapy in the patient with acute lymphoblastic leukemia and lymphoma. Cytotherapy. 2020;22(4):214\u201326.","journal-title":"Cytotherapy"},{"issue":"1","key":"6035_CR21","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3390\/cancers11010047","volume":"11","author":"WL Yu","year":"2019","unstructured":"Yu WL, Hua ZC. Chimeric antigen receptor T-cell (CAR T) therapy for hematologic and solid malignancies: Efficacy and safety-a systematic review with meta-analysis. Cancers (Basel). 2019;11(1):47.","journal-title":"Cancers (Basel)"},{"issue":"7","key":"6035_CR22","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s11912-021-01068-0","volume":"23","author":"NP Patel","year":"2021","unstructured":"Patel NP, Doukas PG, Gordon LI, et al. Cardiovascular toxicities of CAR T-cell therapy. Curr Oncol Rep. 2021;23(7):78.","journal-title":"Curr Oncol Rep"},{"issue":"25","key":"6035_CR23","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1016\/j.jacc.2019.10.038","volume":"74","author":"RM Alvi","year":"2019","unstructured":"Alvi RM, Frigault MJ, Fradley MG, et al. Cardiovascular events among adults treated with chimeric antigen receptor T-cells (CAR-T). J Am Coll Cardiol. 2019;74(25):3099\u2013108.","journal-title":"J Am Coll Cardiol"},{"key":"6035_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, et al. The cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343: d5928.","journal-title":"BMJ"},{"issue":"9","key":"6035_CR25","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603\u20135.","journal-title":"Eur J Epidemiol"},{"issue":"3","key":"6035_CR26","doi-asserted-by":"publisher","first-page":"S270","DOI":"10.1016\/j.bbmt.2019.12.438","volume":"26","author":"JE Brammer","year":"2020","unstructured":"Brammer JE, Braunstein Z, Katapadi A, et al. Cardiovascular toxicity and clinical outcomes following chimeric antigen receptor T-cell infusion (CART) for lymphoid malignancies. Biol Blood Marrow TR. 2020;26(3):S270.","journal-title":"Biol Blood Marrow TR"},{"issue":"8","key":"6035_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002303","volume":"9","author":"JE Brammer","year":"2021","unstructured":"Brammer JE, Braunstein Z, Katapadi A, et al. Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphoma. J Immunother Cancer. 2021;9(8): e002303.","journal-title":"J Immunother Cancer"},{"issue":"17","key":"6035_CR28","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1161\/CIRCULATIONAHA.120.048100","volume":"142","author":"S Ganatra","year":"2020","unstructured":"Ganatra S, Redd R, Hayek SS, et al. Chimeric antigen receptor T-cell therapy-associated cardiomyopathy in patients with refractory or relapsed non-Hodgkin lymphoma. Circulation. 2020;142(17):1687\u201390.","journal-title":"Circulation"},{"issue":"Suppl. 1","key":"6035_CR29","first-page":"A9828","volume":"144","author":"DH Lee","year":"2021","unstructured":"Lee DH, Chandrasekhar S, Jain M, Chavez J, Shah B, Lazaryan A, et al. Active surveillance ofcardiotoxicity with cardiac biomarkers during chimeric antigen receptor t-cell therapy. Circulation. 2021;144(Suppl. 1):A9828\u201338.","journal-title":"Circulation"},{"issue":"1","key":"6035_CR30","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large b-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial. Lancet Oncol. 2019;20(1):31\u201342.","journal-title":"Lancet Oncol"},{"issue":"26","key":"6035_CR31","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory Large b-cell lymphoma. N Engl J Med. 2017;377(26):2531\u201344.","journal-title":"N Engl J Med"},{"issue":"18 Suppl. 1","key":"6035_CR32","doi-asserted-by":"publisher","first-page":"3289","DOI":"10.1016\/S0735-1097(21)04643-X","volume":"77","author":"A Patel","year":"2021","unstructured":"Patel A, Levenson J, Huang J, et al. Prevalence of orthostatic hypotension or frank hypotension after CAR-T hospitalization. J Am Coll Cardiol. 2021;77(18 Suppl. 1):3289\u201399.","journal-title":"J Am Coll Cardiol"},{"issue":"26","key":"6035_CR33","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","volume":"377","author":"SJ Schuster","year":"2017","unstructured":"Schuster SJ, Svoboda J, Chong EA, et al. Chimeric antigen receptor T cells in refractory b-cell lymphomas. N Engl J Med. 2017;377(26):2545\u201354.","journal-title":"N Engl J Med"},{"issue":"3","key":"6035_CR34","doi-asserted-by":"publisher","first-page":"S263","DOI":"10.1016\/j.bbmt.2019.12.428","volume":"26","author":"K Wudhikarn","year":"2020","unstructured":"Wudhikarn K, Pennisi M, Recio MG, et al. Burden and impact of toxicities on outcomes for aggressive b cell non-Hodgkin lymphoma patients after CD19-directed chimeric antigen receptor T cell: Realworld experience. Biol Blood Marrow TR. 2020;26(3):S263\u20134.","journal-title":"Biol Blood Marrow TR"},{"issue":"7","key":"6035_CR35","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.3324\/haematol.2021.280009","volume":"107","author":"RE Steiner","year":"2022","unstructured":"Steiner RE, Banchs J, Koutroumpakis E, et al. Cardiovascular events in patients treated with chimeric antigen receptor T-cell therapy for aggressive B-cell lymphoma. Haematologica. 2022;107(7):1555\u201366.","journal-title":"Haematologica"},{"issue":"Supplement 1","key":"6035_CR36","doi-asserted-by":"publisher","first-page":"6908","DOI":"10.1182\/blood-2023-187338","volume":"142","author":"L Ivan","year":"2023","unstructured":"Ivan L, Jessica RF, Adam G, et al. The impact of cardiovascular vulnerabilities in non Hodgkin lymphoma patients treated with chimeric antigen receptor T cell therapy. Blood. 2023;142(Supplement 1):6908.","journal-title":"Blood"},{"issue":"2","key":"6035_CR37","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001159","volume":"8","author":"H Shalabi","year":"2020","unstructured":"Shalabi H, Sachdev V, Kulshreshtha A, et al. Impact of cytokine release syndrome on card. Shaiac function following CD19 CAR-T cell therapy in children and young adults with hematological malignancies. J Immunother Cancer. 2020;8(2): e001159.","journal-title":"J Immunother Cancer"},{"key":"6035_CR38","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.jaccao.2022.07.014","volume":"4","author":"S Ganatra","year":"2022","unstructured":"Ganatra S, Dani SS, Yang EH, et al. Cardiotoxicity of T-Cell antineoplastic therapies. JACC CardioOncol Primer. 2022;4:616\u201323.","journal-title":"JACC CardioOncol Primer"},{"issue":"7","key":"6035_CR39","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1097\/CCM.0b013e3182186d27","volume":"39","author":"N Pathan","year":"2011","unstructured":"Pathan N, Franklin JL, Eleftherohorinou H, et al. Myocardial depressant effects of interleukin 6 in meningococcal sepsis are regulated by p38 mitogen-activated protein kinase. Crit Care Med. 2011;39(7):1692\u2013711.","journal-title":"Crit Care Med"},{"key":"6035_CR40","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","volume":"34","author":"JN Brudno","year":"2019","unstructured":"Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management. Blood Rev. 2019;34:45\u201355.","journal-title":"Blood Rev"},{"issue":"6","key":"6035_CR41","first-page":"44","volume":"20","author":"A Asnani","year":"2018","unstructured":"Asnani A. Cardiotoxicity of immunotherapy: incidence, diagnosis, and management. Curr OncolRep. 2018;20(6):44.","journal-title":"Curr OncolRep"},{"issue":"6","key":"6035_CR42","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1182\/blood-2013-03-490565","volume":"122","author":"GP Linette","year":"2013","unstructured":"Linette GP, Stadtmauer EA, Maus MV, et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood. 2013;122(6):863\u201371.","journal-title":"Blood"},{"issue":"6","key":"6035_CR43","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1007\/s10238-023-01042-z","volume":"23","author":"M Guo","year":"2023","unstructured":"Guo M, Wang X, Xiao S, et al. Preliminary assessment of cardiotoxicity in chimeric antigen receptor T cell therapy: a systematic review and meta-analysis. Clin Exp Med. 2023;23(6):2041\u201350.","journal-title":"Clin Exp Med"},{"issue":"2","key":"6035_CR44","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jaccao.2020.04.012","volume":"2","author":"B Lefebvre","year":"2020","unstructured":"Lefebvre B, Kang Y, Smith AM, Frey NV, Carver JR, Scherrer-Crosbie M. Cardiovascular effects of CAR T cell therapy: a retrospective study. JACC CardioOncol. 2020;2(2):193\u2013203.","journal-title":"JACC CardioOncol"},{"issue":"22","key":"6035_CR45","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1093\/eurheartj\/ehad117","volume":"44","author":"SS Mahmood","year":"2023","unstructured":"Mahmood SS, Riedell PA, Feldman S, et al. Biomarkers and cardiovascular outcomes in chimeric antigen receptor T-cell therapy recipients. Eur Heart J. 2023;44(22):2029\u201342.","journal-title":"Eur Heart J"},{"issue":"2","key":"6035_CR46","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124(2):188\u201395.","journal-title":"Blood"},{"issue":"26","key":"6035_CR47","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","volume":"127","author":"JN Brudno","year":"2016","unstructured":"Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 2016;127(26):3321\u201330.","journal-title":"Blood"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-024-06035-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-024-06035-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-024-06035-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T16:02:32Z","timestamp":1736006552000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-024-06035-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,4]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6035"],"URL":"https:\/\/doi.org\/10.1186\/s12967-024-06035-4","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,4]]},"assertion":[{"value":"4 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All the authors contributed to the data acquisition and analyses. All the authors have reviewed and approved of the final version of the manuscript and consent to publish.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"There are no conflicts to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8"}}